Scisparc signs definitive agreement to sell mitocarex, computational drug discovery company targeting resistant cancers

Scisparc will sell its mitocarex's shares for $700,000 and exchange its remaining shares for common stock in n2off
SPRC Ratings Summary
SPRC Quant Ranking